Paul Blanchfield

Paul Blanchfield

Chief Executive Officer at
Alpha-9 Oncology, Inc.

Net worth: 7 M $ as of 2026-08-30

45 year
Health Technology
Consumer Services
Commercial Services

Profile

Paul Blanchfield is Chief Executive Officer & Director at Alpha-9 Oncology, Inc. since 2025.
Former roles include President at Lantheus Holdings, Inc. from 2023 to 2025, General Manager-Nordic Baltics at Shire Plc, and Head-US Immunology Business Unit at Takeda Pharmaceutical Co., Ltd. Education includes undergraduate studies at Duke University and graduate and MBA degrees from Stanford University.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
2026-08-16 69,426 ( 0.11% ) 7 M $ 2026-08-30

Paul Blanchfield active positions

CompaniesPositionStart
Chief Executive Officer 2025-11-09

Former positions of Paul Blanchfield

CompaniesPositionEnd
LANTHEUS HOLDINGS, INC. President 2025-11-06
Corporate Officer/Principal -
TAKEDA PHARMACEUTICAL COMPANY LIMITED Corporate Officer/Principal -
See the detail of Paul Blanchfield's experience

Training of Paul Blanchfield

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

32

1st degree connections

6

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies6

Commercial Services

Consumer Services

Consumer Services

Health Technology

Health Technology

Health Technology

  1. Stock Market
  2. Insiders
  3. Paul Blanchfield